Market Overview

Oppenheimer Reiterates Perform Rating on Amarin Following AMR-102 Study

Share:
Related AMRN
20 Stocks Moving In Monday's Pre-Market Session
Watch These 7 Huge Call Purchases In Thursday Trade
Your Daily Pharma Scoop: Juno Surges On Takeover Rumors, AEterna Zentaris Achieves Another Milestone, Spark Granted ODD (Seeking Alpha)

In a report published Friday, Oppenheimer analyst Akiva Felt reiterated a Perform rating and $8.00 price target on Amarin (NASDAQ: AMRN).

In the report, Oppenheimer noted, “Amarin reported that the Phase 1 study of AMR-102 (fixed-dose combination of Vascepa+rosuvastatin) demonstrated positive pharmacokinetic and safety results. Specifically, the AMR-102 combination product was absorbed in the same manner as taking the two drugs independently. These findings should not be surprising, in our view, given the drug-drug-interaction (DDI) studies conducted as part of Vascepa's NDA which demonstrated that Vascepa did not inhibit the metabolism of statins. That said, we view the Phase 1 results to be incrementally positive, demonstrating that AMR-102 is formulated in a viable manner. Our focus remains on Vascepa as the key driver for AMRN shares. Reiterate Perform.”

Amarin closed on Thursday at $6.30.

Latest Ratings for AMRN

DateFirmActionFromTo
Oct 2016CitigroupInitiates Coverage OnBuy
Oct 2016Cantor FitzgeraldInitiates Coverage onBuy
Oct 2016Cantor FitzgeraldInitiates Coverage onBuy

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Akiva Felt OppenheimerAnalyst Color Reiteration Analyst Ratings

 

Related Articles (AMRN)

View Comments and Join the Discussion!